Companies /Healthcare
AbCellera Biologics Inc
NASDAQ: ABCL Biotechnology
$12.55
▲ $0.53 (+4.37%) today
Markets closed · 12:43am ET

AbCellera Biologics (ABCL) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
60%
EPS beat rate
+22.21%
Avg. EPS surprise
Consecutive EPS misses
ABCL vs Market · 30-day return after each reportABCLS&P 500
0%+30%+60%+0.7%+2.4%Q2 25−3.6%+2.5%Q3 25+2.5%−8.5%Q4 25+5.9%+0.5%Q1 26+75.2%−0.3%Q2 26
0%+30%+60%Q2 25Q3 25Q4 25Q1 26Q2 26
ABCL EPS Trend · estimate vs actualEstimateActual
$-0.18$-0.12$-0.06$-0.16$-0.12Q2 25$-0.16$-0.19Q3 25$-0.18$-0.03Q4 25$-0.20$-0.14Q1 26$-0.17$-0.18Q2 26
$-0.18$-0.12$-0.06Q2 25Q3 25Q4 25Q1 26Q2 26
ABCL Revenue Trend · estimate vs actualEstimateActual
$0$20.0M$40.0M$6.2M$17.1MQ2 25$6.3M$9.0MQ3 25$6.7M$44.9MQ4 25$5.8M$8.3MQ1 26$7.8M$4.1MQ2 26
$0$20.0M$40.0MQ2 25Q3 25Q4 25Q1 26Q2 26

How Often Does AbCellera Biologics Beat Earnings Estimates?

AbCellera Biologics beat EPS estimates in 3 of its last 5 reported quarters.

ABCL quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 $-0.18 est. $-0.17 −9.09% $4.1M est. $7.8M −48.39%
Q1 2026 $-0.14 est. $-0.20 +29.11% $8.3M est. $5.8M +42.49%
Q4 2025 $-0.03 est. $-0.18 +83.33% $44.9M est. $6.7M +569.55%
Q3 2025 $-0.19 est. $-0.16 −17.28% $9.0M est. $6.3M +41.40%
Q2 2025 $-0.12 est. $-0.16 +25.00% $17.1M est. $6.2M +173.69%

Figures from SEC filings and company reports. Not investment advice.